Original Article

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
Ghasemi A MD1,2, Keikhaei B MD2, Ghodsi R MD3

1. Assistant professor of pediatric hematology and oncology, faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2. Associate professor of pediatric hematology and oncology, Jondishapour University of Medical Sciences, Ahvaz, (research center for thalassemia and hemoglobinopathy).
3. Department of Medical Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad/Iran

Received: 31 May 2014
Accepted: 23 August 2014

Abstract

Background
Sickle hemoglobin is the most common abnormal hemoglobin in the United States. Hemoglobin S arises as a result of a single amino acid substitution (glutamic acid to valin at position 6 of the β-globine chain) (1). The presence of fetal hemoglobin (HbF) plays a relatively protective role since a significant amount of HbF interferes with HbS polymerization, the pathogenesis mechanism of the vaso-occlusive symptoms that are the major contributor of the morbidity and mortality of this condition.

Thalassemia major and thalassemia intermedia have no specific molecular correlate but encompass a wide spectrum of clinical and laboratory abnormalities (3). Patients referred to as having thalassemia major are usually those who come to medical attention in the first year of life and subsequently require regular transfusions to survive. Those who present later or who seldom need transfusions are said to have thalassemia intermedia (4).

Hydroxyurea (HU), an S-phase-specific and non-DNA-hypomethylating chemotherapeutic agents is capable of inducing HbF synthesis.

Materials and Methods
This study was done on 56 patients, 28 patients with sickle cell anemia (SCA) and 28 patients with intermediate or major β-thalassemia.

Start dose of HU was 10 mg/kg per day and increased by 5 mg/kg per day every 4–6 weeks until toxicity or according to clinical response.

Results
The side effects were dermatologic in 39.28%, neurologic 23.2%, gastrointestinal 17.5% and hematologic 10.71% of patients. The statistical analysis didn't show significant relationship between variables such as history of blood transfusion, duration of HU treatment, age of start HU, age of diagnosis, dose of HU and ethnic with occurrence of HU adverse effects.

Conclusion
The HU therapy in our patients tolerated well and side effects were minor to moderate, benign and transient.

Key words
Side effects, hydroxyurea, β-Thalassemia, Sickle cell anemia

Introduction
Sickle hemoglobin is the most common abnormal hemoglobin in the United States. Hemoglobin S arises as a result of a single amino acid substitution (glutamic acid to valin at position 6 of the β-globine chain) (1).

In patients with sickle cell anemia, the presence of fetal hemoglobin (HbF) in infancy plays a relatively protective role since a significant amount of HbF interferes with HbS polymerization, the pathogenesis mechanism of the vaso-occlusive symptoms that are the major contributor of the morbidity and mortality of this condition (2).
synthesis, the effect of hydroxyurea and other antimetabolites on HbF synthesis is mainly mediated by their cytotoxic properties (5).

Hydroxyurea produces fetal hemoglobin production via the reactivation of Y genes as a result of some unknown molecular mechanisms (6). The commonest side-effect is dose-dependent myelosuppression: Although this is usually transient (7).

Cutaneous side-effect includes nail hyperpigmentation, which is common and increased skin pigmentation, especially on the palms and soles. Hydroxyurea is associated with development of leg ulcers in myeloproliferative disease and some studies have rates of up to 30% in SCD patients on hydroxyurea (8,9).

Nausea, rash and other gastrointestinal upsets have been described with hydroxyurea (10). Hydroxyurea is renally excreted and small increases in creatinine are sometimes seen on treatment.

Materials and Methods
This was a cross-sectional study, sampling was simple random, data gathered with a questionnaire. We included 56 patients, 28 patients with sickle cell anemia and 28 patients with intermediate or major β-thalassemia.

Exclusion criteria for all patients were creatinine level more than twice the upper limit of normal for age or greater than 1.5 mg/dl and active liver disease. These patients visited monthly by pediatric specialist and pediatric hematologist-oncologist and evaluated about hydroxyurea complications. Laboratory tests include CBC (complex blood count) and liver enzymes performed monthly. Start dose of HU was 10 mg/kg per day and increased by 5 mg/kg per day every 4-6 weeks until toxicity or according to clinical response or total dose 35mg/kg/day.

The variables shush as gender, age, ethnic, age of diagnosis, age of start HU, history of blood transfusion, duration of HU treatment, dose of HU, recorded and compared correlation with side effects such as dermatologic, neurologic, hematologic, hepatic and others.

Statistical analysis
The data analyzed with software SPSS version 16 and significant level was P-Value < 0.05.

Results
This study was to evaluate the side effects of HU treatment in 56 patients, 24 male (42.9%) and 32 female (57.1%) our report investigate results in two group of patients

a) Twenty-eight Patients with sickle cell anemia treated with HU.

b) Twenty-eight Patients with major and β-thalassemia.

Ethnic of our patients were 37 Arabian (66.1%) and 19 non-Arabian (33.9%) They had a median age of 17.5±8.55 years (range: 4-52 years).

Forty-five patients (80.4%) had history of transfusion, 29 of transfused patients suffered complication.

Side effects of HU have been recorded in 37 (66.1%) patients (Table I).

| Side Effect            | Number of Patients | Percentage |
|------------------------|--------------------|------------|
| Dermatologic           | 22                 | 39.28%     |
| Hair loss              | 19                 | 33.9%      |
| Hyperpigmentation      | 6                  | 10.7%      |
| Skin rash              | 2                  | 3.57%      |
| Nail hyperpigmentation | 1                  | 1.7%       |
| Gastrointestinal       | 10                 | 17.5%      |
| Nausea                 | 3                   | 5.36%      |
| Vomiting               | 5                   | 8.9%       |
| Abdominal pain         | 2                   | 3.57%      |
| Anorexia               | 2                   | 3.57%      |
| Constipation           | 1                   | 1.7%       |
| Neurologic             | 13                  | 23.2%      |
| Headache               | 16                  | 16%        |
| Vertigo                | 3                   | 3.57%      |
| Drowsiness             | 1                   | 1.7%       |
| Seizure                | 1                   | 1.7%       |
| Hepatic                | 4                   | 7.1%       |
| Increase AST-ALT       | 3                   | 5.36%      |
| Weight gain            | 2                   | 3.57%      |
| Skin ulcer             | 1                   | 1.7%       |
| Edema                  | 1                   | 1.7%       |
| Hematologic            | 8                   | 14.3%      |
| Platelets decrease     | 2                   | 3.57%      |
| Neutropenia            | 2                   | 3.57%      |
| Decrease in Hb level   | 2                   | 3.57%      |

115                                                                          Iranian Journal of Pediatric Hematology Oncology Vol4.No3

Downloaded from ijpho.ssu.ac.ir at 22:51 IRDT on Sunday June 14th 2020
Table I: Side effects of hydroxyurea

| Side effects | Patients (%) |
|--------------|--------------|
| **Neurologic 13 (23.2%)** | | |
| Headache | 13 (16) |
| Vertigo | 2 (3.57) |
| Drowsiness | 1 (1.7) |
| Seizure | 1 (1.7) |
| **Dermatologic 22 (39.28%)** | | |
| Hair Loss | 19 (33.9) |
| Hyper pigmentation | 6 (10.7) |
| Skin ulcer | 1 (1.7) |
| Skin rash | 2 (3.57) |
| Nail hyper pigmentation | 1 (1.7) |
| **Gastrointestinal 10 (17.5%)** | | |
| Abdominal Pain | 5 (8.9) |
| Nausea and vomiting | 3 (5.3) |
| Constipation | 1 (1.7) |
| Anorexia | 2 (3.57) |
| **Hematologic 6 (10.7%)** | | |
| Decreased PLT | 2 (3.57) |
| Decreased HB | 2 (3.57) |
| Neutropenia | 2 (3.57) |
| **Others** | | |
| Increased AST, ALT | 4 (7.4) |
| Weight gain | 2 (3.57) |
| Edema | 1 (1.7) |

Discussion
The most common side effects were hair loss and headache in 33.9% and 16% of patients respectively. Hyperpigmentation has been recorded in 10.7% patients.

The side effects were dermatologic in 39.28% (23), neurologic 23.2% (13), gastrointestinal 17.5% (10) and hematologic 10.71% (6) of patients.

Chick and coworkers (2006) didn’t encounter leucopenia or abnormality in renal and liver functions. One patient had reduction in the nucleated red blood cell in peripheral blood. (7)

In Benedict study recorded that the most common side effect was dermatologic and hyper pigmentation was most common dermatologic side effect (8).

In our study, the most common side effect was dermatologic in 39% patients.

Zargari and co workers retorted, the cutaneous effects of HU have been described for patients with sickle cell anemia, myeloproliferative disorders, and psoriasis, there are no reported of cutaneous adverse effects from HU when used for patients with intermediate thalassemia (9). Ferguson and coworkers described that HU improved clinical outcomes in patients with sickle cell anemia (10).

Karimi and coworkers reported that dermatologic side effects were most commonly seen, followed by neurologic and gastrointestinal adverse effects. There were not any reports of hematologic toxicity or any signs of bone marrow suppression during HU treatment (11).

Statistical analysis showed a positive correlation between advancing age and the presence of adverse effects during HU treatment, but there were not any significant relations among gender, HU dose and duration of HU treatment and the presence of adverse effects (P>005).

Hope and coworkers suggests that hydroxyurea is safe and effective in sickle cell disease (12).

In our study, the statistical analysis didn't show significant relationship between variables such as history of blood transfusion, duration of HU treatment, age of start HU, age of diagnosis, dose of HU and ethnic with occurrence of HU adverse effects.

Conclusion
Based on the evidence of several studies, HU plays an important role in the management of a number of complication of SCD and decrease transfusion...
number of thalassemic patients and saves them from side effects of blood transfusions.
The HU therapy in our patients tolerated well and side effects were minor to moderate, benign and transient. We recommend, to starting low dose of HU (10 mg/kg per day) and increase dose slowly in pediatric and adult patients with SCA and thalassemia can be tolerated well without serious side effects.

**Conflict of interest**
The authors have no conflict of interest.

**References**
1. Lanzkowsky A. Manual of pediatric hematology and oncology, Fifth Edition, 2011:210-246.
2. Robert P, Ferguson, Anuradha Arun, Chris Carter, Stanley D Walker, Oswaldo Castro. Hydroxyurea treatment of sickle cell anemia in hospital-based practices. American journal of hematology 2002, 70:326-328.
3. Camaschella C, Capellini MD. Thalassemia intermedia. Heamatologica 1995, 80: P58-68.
4. Cao A. Diagnosis of β-Thalassemia intermedia at presentation. In: Fucharoens, Rowely PT, Paul NW, eds. Thalassemia pathophysiology and management. Part B, Vol 23 of Birth defects: Original article series. Newyork. Alan R. Liss, 1988: 219-226.
5. Atweh GF, loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and β-Thalassemia. Semin hematol 2001, 38: 367-373.
6. Charache S, Terrin MI, Moore RD, et al. effect of hydroxyurea on frequency of painful crisis in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995, 332: 1317-1322.
7. Chik KW, Lee V, Shing MMK, Li CK, Hydroxyurea treatment in β-Thalassemia intermedia, HK J Pediatric 2006; 11: 20-21.
8. Benedicate C, Neonate MG, Girot R, Aractingis S, Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch dermatol 2001: 137:467-470.
9. Zargari O, Kimyai-asadi A, Jafroodi M, Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch dermatol 2001: 137:467-470.
10. Ferguson RP, Arun A, Carter C, Walker SD, Castro O, Hydroxyurea treatment of sickle cell anemia in hospital based practices. AM J hematol 2002 Aug: 70(4): 326-328.
11. Karimi M, Cohan N, Moosavizadeh K, Javad MF, Sezaneh H. Adverse effects of hydroxyurea in β-Thalassemia intermedia patients; 10 years experience J of Pediatric hematol-oncology, Apr 2010; Vol 27; No 3: P; 205-211.
12. Hope C, Vinchinsky E, Quirolo K, Van Warmerdam J, Allan K, Styles L, Use of hydroxyurea in children ages 2-5 years with sickle cell disease, Journal of pediatric hematology oncology, July/Agust 2000:p330-334.